Arcus Biosciences Revenue 2017-2023 | RCUS
Arcus Biosciences revenue from 2017 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Arcus Biosciences Annual Revenue
(Millions of US $) |
| 2022 |
$112 |
| 2021 |
$383 |
| 2020 |
$78 |
| 2019 |
$15 |
| 2018 |
$8 |
| 2017 |
$1 |
| 2016 |
$ |
Arcus Biosciences Quarterly Revenue
(Millions of US $) |
| 2023-03-31 |
$25 |
| 2022-12-31 |
$34 |
| 2022-09-30 |
$34 |
| 2022-06-30 |
$27 |
| 2022-03-31 |
$18 |
| 2021-12-31 |
$355 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
$9 |
| 2021-03-31 |
$9 |
| 2020-12-31 |
$10 |
| 2020-09-30 |
$65 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$2 |
| 2019-12-31 |
$10 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$2 |
| 2019-03-31 |
$2 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$4 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.536B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
